This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Part 1 of this article compares NLY’s recent leverage, hedging coverage ratio, quarterly BV, economic loss, and current valuation to twenty mREIT peers.
ANH NYMTO ORC CHMI NYMTP CIM AI CMO TWO AGNC AIW GPMT MO WMC NRZ AIC CYS 511505 CAPITALT MITT MFO DX NLY ARR BXMT MFA IVR NYMT
WallStars show positive broker target price-upsides. 66 displayed 10%+ forward yield, at $2+ prices, and $10M+ market caps as of 8/9/18. Yields above 11.88% narrowed this WallStar list to 30.
SNR.WI NGL SNR AIC MCQ MMLP MCV BBDC PER HCLP SNR MCX AI GMLP MDLY CVRR AIW SNMP MCC
Following continued requests, this article analyzes fixed-rate agency MBS price movements during the third quarter of 2018 (through 8/10/2018).
NYMTO ORC FNMA CHMI NYMTP CIM AI TWO AGNC AIW MO WMC NRZ AIC CYS TRI MITT FMCKI FMCKJ FMCCO FMCCP FMCCM FMCCN MFO FMCCI DX NLY FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL ARR MFA FMCC IVR NYMT FMCCS FMCCT
424B5 Table of Contents Filed Pursuant to 424(b)(5) File No. 333-215384 PROSPECTUS SUPPLEMENT (To prospectus dated February 17, 2017) Up to 12,597,423 Shares <
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
On 7/25/2018, AGNC reported results for the second quarter of 2018. AGNC reported comprehensive income of $148 million and a non-tangible BV as of 6/30/2018 of $19.68 per common share.
NYMTO ORC CHMI NYMTP AI CMO TWO AGNC AIW MO NRZ AIC CYS ARR BXMT 511505 NYMT CAPITALT
ai-8k_20180630.htm UNITED STATES SECUR
China is already a major player in digital technologies at home and around the world, and it has enormous growth potential. As digital forces shake the status quo and restructures value chains, an even more globally competitive Chinese economy and dynamic firms can emerge. China continues to shrink the technology gap between itself and more developed countries and lead the world in the adoption of ecommerce and mobile payments.
VR BABA AI ATHM CTRP BIDU
I am projecting AGNC will report a minor decrease in quarterly BV for the second quarter of 2018. Most agency peers will also experience a similar type of BV decrease.
NYMTO ORC CHMI NYMTP CIM AI TWO AGNC AIW MO WMC NRZ AIC CYS MTGE MITT MFO DX NLY ARR MFA HTS IVR NYMT
I am projecting AGNC will report a combined modest-notable net unrealized loss on available-for-sale securities and investment securities measured at FMV for the second quarter of 2018.
NYMTO ORC FNMA CHMI NYMTP CIM AI TWO AGNC AIW MO WMC NRZ AIC CYS TRI MITT FMCKI FMCKJ FMCCO FMCCP FMCCM FMCCN MFO FMCCI DX NLY FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL ARR MFA FMCC HTS IVR NYMT FMCCS FMCCT
Fairly similar to the prior quarter, I am projecting AGNC will report a modest-notable gain regarding the company’s derivative instruments and other securities for the second quarter of 2018.
NYMTO MTGE ORC CHMI NYMTP AI TWO AGNC AIW NRZ AIC NLY CYS ARR NYMT
2018-08-13 - Asif
Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...
2018-08-13 - Asif
Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...
2018-08-13 - Asif
Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...
as of ET